



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAY 13 2002 APPLICANT: J. Gut, et al

ATENT & TRADEMARK OFFICE SERIAL NO.: 10/005,666

FILED: November 2, 2001

FOR: METHOD AND SYSTEM FOR REGISTRATION
IDENTIFYING AND PROCESSING OF DRUG SPECIFIC
DATA

EXAMINER: --

GROUP: 1619

COPY OF PAPERS
ORIGINALLY FILED

Commissioner for Patents
Washington, D.C. 20231

RECEIVED

MAY 15 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 CFR sections 1.97 and 1.98, applicant respectfully requests that the document listed on the attached form PTO-1449, be made of record and considered in connection with the examination of this application. A copy of the listed document is enclosed.

No fee is due with this Information Disclosure Statement as it is being submitted before the first Office Action on merits.

Respectfully submitted,

Alexander Zinchuk
Alexander Zinchuk
Reg. No. 30,541

Dated: May 3, 2002
Sidley Austin Brown & Wood LLP
875 Third Avenue
New York, NY 10022
Tel: (212) 906-2799 (Ext. 21236)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail and addressed to: Commissioner for Patents, Washington, D.C. 20231 on May 3, 2002.

**COPY OF PAPERS
ORIGINALLY FILED**

Sheet 1 of 1

Form PTO-1449 LIST OF PRIOR ART CITED BY APPLICANT O I P E JCSA MAY 13 2002 EXAMINER & TRADEMARK OFFICE	Docket No.: DT-6018		Serial No.: 10/005,666
	Applicant(s): J. Gut, et al.		
	Filing Date: November 2, 2001	Group: 1619	

U. S. PATENT DOCUMENTS

Exam. Init.		Document Number	Date	Name	Class	Subclass	Filing Date if appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

RECEIVED

MAY 15 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

		Document Number	Date	COUNTRY	Class	Subclass	TRANSLATION Yes No
	AL						
	AM						
	AO						
	AP						

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AR	Dale R. Pfost, et al., a SNAPSHOT: Pharmacogenetics and the Future of Drug Therapy, Trends in Biotechnology, Elsevier, Vol. 18, No. 8, p.p. 334-338	
	AS	
AT		

EXAMINER	DATE CONSIDERED
----------	-----------------